Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma

Ann Hematol. 2023 Jan;102(1):223-225. doi: 10.1007/s00277-022-05039-8. Epub 2022 Nov 17.

Authors

Kohei Shinmura¹, So Okubo¹, Saori Kadota¹, Hitomi Nakayama¹, Aki Sakurai¹, Shuhei Kurosawa¹, Chisako Ito¹, Yoshinobu Aisa¹, Tomonori Nakazato²

Affiliations

¹ Department of Hematology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawanishi-Cho, Kanagawa-Ku, Yokohama, 221-0855, Japan.
² Department of Hematology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawanishi-Cho, Kanagawa-Ku, Yokohama, 221-0855, Japan. n-tomo@eurus.dti.ne.jp.

PMID: 36394579
DOI: 10.1007/s00277-022-05039-8

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bendamustine Hydrochloride / therapeutic use
Humans
Immunoconjugates* / therapeutic use
Lymphoma, Large B-Cell, Diffuse* / diagnostic imaging
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Non-Hodgkin* / drug therapy
Neurolymphomatosis*
Rituximab / therapeutic use

Substances

polatuzumab vedotin
Rituximab
Bendamustine Hydrochloride
Immunoconjugates